News articles about ChemoCentryx (NASDAQ:CCXI) have been trending somewhat positive this week, according to Accern. Accern identifies negative and positive media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. ChemoCentryx earned a daily sentiment score of 0.22 on Accern’s scale. Accern also assigned news articles about the biopharmaceutical company an impact score of 45.947626867269 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
CCXI has been the topic of a number of research analyst reports. BidaskClub downgraded ChemoCentryx from a “strong-buy” rating to a “buy” rating in a report on Thursday, August 10th. Zacks Investment Research upgraded ChemoCentryx from a “sell” rating to a “hold” rating in a report on Friday, August 18th. Finally, Cowen and Company reiterated a “hold” rating on shares of ChemoCentryx in a report on Tuesday, August 8th.
ChemoCentryx (NASDAQ:CCXI) traded up 0.39% on Thursday, hitting $7.81. The company’s stock had a trading volume of 79,232 shares. ChemoCentryx has a 12 month low of $5.19 and a 12 month high of $10.80. The firm has a 50 day moving average of $7.39 and a 200 day moving average of $7.82. The firm’s market cap is $380.39 million.
ChemoCentryx (NASDAQ:CCXI) last posted its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by ($0.02). The firm had revenue of $8.94 million for the quarter. Equities research analysts forecast that ChemoCentryx will post ($0.90) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This article was originally published by Ticker Report and is the property of of Ticker Report. If you are reading this article on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright law. The legal version of this article can be viewed at https://www.tickerreport.com/banking-finance/2956118/chemocentryx-ccxi-earns-coverage-optimism-rating-of-0-22.html.
ChemoCentryx, Inc is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact.
Receive News & Ratings for ChemoCentryx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx Inc. and related companies with MarketBeat.com's FREE daily email newsletter.